

Special Issue

New Predictive Biomarkers for Ovarian Cancer

Message from the Guest Editor

The majority of women diagnosed with ovarian cancer present with advanced stage and are treated with standard chemotherapy. A number of novel predictive biomarkers, including tumor mutation burden, CCNE1 and other cell cycle genes, and BRCA1/2 and other DNA repair related genes, make a patient potentially eligible for a currently approved targeted therapy or immunotherapy. A number of targeted agents are in development for novel and existing biomarkers in ovarian cancer. The purpose of this Special Issue is to review new and emerging predictive biomarkers important in ovarian cancer that may make a patient eligible for treatment with novel targeted therapies or be a target for novel drug development.

Guest Editor

Prof. Dr. Jill Marie Kolesar

Markey Cancer Center, University of Kentucky, Lexington, Lexington, KY, USA

Deadline for manuscript submissions

closed (31 December 2020)



Diagnostics

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 5.9
Indexed in PubMed



mdpi.com/si/46254

Diagnostics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diagnostics@mdpi.com

[mdpi.com/journal/
diagnostics](https://mdpi.com/journal/diagnostics)





Diagnostics

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 5.9
Indexed in PubMed



[mdpi.com/journal/
diagnostics](https://mdpi.com/journal/diagnostics)



About the Journal

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.6 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).